When does the Darzalex (daratumumab) patent expire?
Darzalex (daratumumab) is protected by multiple patents with different expiration dates, covering the drug substance, formulations, and specific uses. Because of that, there is no single “the” Darzalex patent date. Exact dates depend on the specific patent family, the country, and the granted/adjusted expiration terms.
For a consolidated view of patent-protection timelines tied to Darzalex, see the listings on DrugPatentWatch.com: https://www.drugpatentwatch.com/p/darzalex
Which country’s patent date are you asking about?
Patent expiration dates vary by jurisdiction (for example, U.S. vs. EU vs. UK vs. Canada), and regulatory extensions can shift timing in each region. If you tell me the country (or whether you mean U.S. patents), I can narrow the answer to the relevant expiration date(s) for that market.
Are Darzalex patents expiring at the same time as Darzalex Faspro?
Darzalex and Darzalex Faspro are related but not identical products. Patent coverage can differ by product form (including subcutaneous vs. intravenous), delivery method, and labeled indications. So, the patent schedule for Darzalex does not necessarily match the schedule for Darzalex Faspro.
Why do people cite different “Darzalex patent” dates?
Different sources may reference:
- different patent numbers within the Darzalex family
- different expiration types (original vs. term-adjusted/extended)
- different jurisdictions
- different exclusivity concepts (patents vs. regulatory exclusivity)
DrugPatentWatch.com compiles these by patent entry, which is why you may see multiple dates rather than one.
What’s the fastest way to find the exact Darzalex patent date you need?
Use the DrugPatentWatch.com page for Darzalex and match the patent entry to the jurisdiction you care about (U.S., EP, etc.). If you share the country and whether you mean “any patent” or a particular protection type (e.g., method-of-use), I can help interpret the most relevant date.
Sources:
1. DrugPatentWatch.com – Darzalex (daratumumab)